Patients with thyroid eye disease, a condition that causes the eyes to bulge forward due to swelling behind the eyeball, now have a second targeted drug option after the FDA approved veligrotug. The approval covers both active and chronic forms of the disease and is backed by two Phase 3 randomized trials, THRIVE and THRIVE-2, that measured whether the drug could reduce eye protrusion by a clinically meaningful margin. For the roughly half of TED patients whose disease persists beyond the acute inflammatory window, the chronic-disease trial tested veligrotug in adults with disease onset greater than 15 months, a population that until now had limited alternatives to surgery.
What veligrotug changes for chronic TED patients facing surgery
Thyroid eye disease inflames and expands the fat and muscle tissue behind the eye, pushing the eyeball forward in a process called proptosis. When the condition becomes chronic, the tissue changes harden, and the standard remedy has been orbital decompression surgery, a procedure that removes bone or fat from the eye socket to make room. Veligrotug targets the insulin-like growth factor 1 receptor, blocking a signaling pathway that drives the tissue expansion.
The practical question is whether wider prescribing of veligrotug will reduce the number of chronic TED patients who eventually need that surgery. If the drug can reliably shrink proptosis by at least 2 millimeters, the threshold used in both trials, many patients could avoid an invasive procedure that carries risks of double vision and altered facial appearance. Insurance claims data should eventually show whether surgical volumes decline once the drug reaches steady prescribing, but that signal will take at least two years to emerge clearly.
For patients and their physicians, the immediate change is concrete: a drug option now exists for chronic TED that was tested in a randomized, double-masked, placebo-controlled clinical trial specifically designed for that population. The THRIVE-2 trial enrolled adults whose disease had been present for more than 15 months, a cutoff that separates chronic from active disease and that defines the group most likely to be told surgery is the only remaining step. Having a rigorously studied medical therapy in this setting allows clinicians to discuss a non-surgical path with patients who previously faced a binary choice between watchful waiting and the operating room.
Two Phase 3 trials anchor the FDA’s decision on veligrotug
The evidence package rests on two distinct trials. THRIVE studied veligrotug in active thyroid eye disease and has been published as a peer-reviewed Phase 3 study with a randomized, double-masked, placebo-controlled design in the medical literature. THRIVE-2 extended the investigation to chronic TED, reporting efficacy and safety results at its 15-week primary timepoint in a conference abstract presented at the ENDO/AACE meeting and accessible through an open-access summary. Both trials used proptosis responder criteria as the prespecified primary endpoint, meaning the main measure of success was the proportion of patients whose eye protrusion decreased by at least 2 millimeters.
The FDA’s own substance registry lists veligrotug under UNII Z9U2SS9ZC8, the standardized identifier that links the drug across labeling, pharmacovigilance databases, and prescribing systems. That registry entry confirms the agency has formally cataloged the molecule for regulatory tracking and provides a backbone for integrating veligrotug into electronic health records, pharmacy systems, and adverse-event reporting tools.
Having two trials that cover different disease stages is significant because TED behaves differently in its active and chronic phases. Active disease involves ongoing inflammation, while chronic disease features scarring and fibrotic tissue remodeling. Demonstrating efficacy in both stages means physicians can consider the drug regardless of where a patient falls on the disease timeline, rather than reserving it for a narrow treatment window. In practice, this could simplify treatment algorithms: instead of waiting to see whether inflammation subsides on its own before intervening, clinicians may be more willing to introduce veligrotug earlier and continue its use as the disease transitions into a chronic pattern.
The trials also help refine expectations about response. The use of a 2-millimeter proptosis threshold reflects consensus that smaller changes, while measurable, may not translate into noticeable symptom relief or cosmetic benefit. By anchoring regulatory approval to that benchmark, the FDA is effectively endorsing it as a clinically meaningful target. For patients, that framing can guide conversations about what success looks like: not necessarily a complete return to pre-disease eye appearance, but a measurable and visible reduction that may ease discomfort, improve eyelid closure, and reduce social self-consciousness.
Gaps in long-term data and real-world safety tracking
Several questions remain open. The THRIVE-2 chronic TED data reported so far cover only 15 weeks, the primary timepoint. Whether the proptosis reduction holds at six months, one year, or longer is not yet available in the public trial record. For a chronic condition where patients may need ongoing management for years, that gap matters. Without longer follow-up, it is unclear whether patients will require repeat treatment courses, maintenance dosing, or combination strategies with other therapies to sustain benefit.
Full peer-reviewed subgroup analyses and detailed adverse-event tables from the THRIVE program have not yet appeared in the primary records available through the National Library of Medicine. That limits the ability to answer granular questions, such as whether smokers, older adults, or patients with more severe baseline proptosis respond differently, or whether certain comorbidities increase the risk of side effects. Clinicians who treat diverse patient populations will be watching for those breakdowns to refine their prescribing decisions.
Patient-reported outcome scores tied to quality of life, such as how much the eye changes affect daily activities, appearance concerns, or visual function, are also absent from the published primary sources. The proptosis responder endpoint is an objective anatomical measure, but it does not capture the full range of symptoms that drive patients to seek treatment in the first place, including pain, grittiness, tearing, and difficulty with reading or driving. Future publications that integrate subjective assessments with the anatomical data will be important for understanding how much veligrotug changes day-to-day experience, not just measurements on a CT scan or exophthalmometer.
Post-approval safety monitoring will be the next major checkpoint. Real-world pharmacovigilance data, which track adverse events reported after a drug enters routine clinical use, have not yet accumulated for veligrotug. The FDA’s substance record provides the infrastructure for that tracking, but the signal will build only as prescribing volume grows over the coming months. Rare side effects that do not appear in trials of a few hundred participants may emerge when thousands of patients are treated, and regulators will rely on spontaneous reports, registry data, and possibly post-marketing studies to characterize those risks.
Physicians considering veligrotug for chronic TED patients should watch for the full peer-reviewed publication of THRIVE-2 results, which will include subgroup breakdowns and longer follow-up data. Patients currently weighing orbital decompression surgery may want to discuss with their ophthalmologist or endocrinologist whether a trial of veligrotug is appropriate before proceeding to an irreversible operation. For some, the drug may offer a chance to delay or avoid surgery altogether; for others, it may serve as a bridge that improves eye position and soft-tissue status, potentially simplifying any later surgical intervention.
As veligrotug moves from trial settings into routine care, its ultimate role in thyroid eye disease management will depend on how durable its benefits prove to be, how its safety profile looks in broader use, and how payers handle coverage decisions for both active and chronic disease. For now, its approval marks a meaningful expansion of options for a group of patients who have long faced limited choices once their disease became chronic and structurally fixed.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
